this compound tfa

(S,R,S)-AHPC TFA (VHL ligand 1 TFA) (VH032-NH2 TFA) is a VH032-based ligand designed for von Hippel-Lindau (VHL) protein recruitment. This compound can be linked to protein ligands (e.g., BCR-ABL1) using a linker to create PROTACs (e.g., GMB-475), which effectively induce the degradation of BCR-ABL1, demonstrated by an IC50 of 1.11 μM in Ba/F3 cells.

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate composed of an E3 ligase ligand-linker that integrates a Thalidomide-based cereblon ligand and a linker moiety. This compound is used as a component in PROTAC BRD2/BRD4 degrader-1, a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

DOTAGA.(SA.FAPi)2 TFA is an effective dimeric fibroblast activation protein inhibitor (FAPi). This compound holds potential for use in cancer diagnostic research.

IIQLPEIVVV TFA serves as a specific inhibitor targeting the Drp1-Mff interaction. This compound discriminates between physiological and pathological fission, hindering physiological fission which leads to mitochondrial dysfunction. IIQLPEIVVV TFA is also utilized in research related to Huntington's disease.

Angiotensin I-13C6,15N (human, mouse, rat) TFA is a labeled version of Angiotensin I, using isotopes 13C and 15N, specifically targeted for human, mouse, and rat studies. This compound serves as a precursor to angiotensin II, which is formed through the cleavage by angiotensin-converting enzyme (ACE).

(R)-Aminocarnitine (Emeriamine) TFA is an inhibitor of fatty acid oxidation, effective in decreasing hyperglycemia and ketosis. This compound is used in research of metabolic diseases.

ADWX 1 TFA is a novel peptide that potently targets and inhibits the Kv1.3 channel, with an IC50 of 1.89 pM. It specifically suppresses the activity of the Kv1.3 channel, in addition to inhibiting initial calcium signaling and NF-κB activation. This compound has been shown to ameliorate symptoms in rats with experimental autoimmune encephalomyelitis (EAE). ADWX 1 TFA is utilized in research focused on T-cell-mediated autoimmune diseases.

4'-Hydroxytamoxifen TFA, a salt form of a metabolite of Tamoxifen, demonstrates higher affinity for ER compared to Tamoxifen itself. This compound induces non-apoptotic cytotoxicity in human endometrial adenocarcinoma cells.

Gamma-Glu-AbuTFA is the TFA salt form of Gamma-Glu-Abu. This compound acts as an agonist for the calcium sensing receptor (CaSR), activating CaSR in HEK-293 cells with an EC50 of 0.21 μM.

(E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium TFA (Compound 4a) functions as a Gram-negative outer membrane permeabilizer by targeting Met47 in LptA to disrupt LptA/LptC interactions, exhibiting synergistic antibacterial activity. This compound, when in the form of (trifluoromethanesulfonate), enhances the efficacy of pol B against both wild-type and multi-drug resistant A. baumannii and E. coli strains. Additionally, (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) serves as an adjuvant for antibiotics combating multi-drug resistant Gram-negative bacteria.

PBA-1105 TFA is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. This compound selectively binds to the exposed hydrophobic regions of misfolded proteins, promoting their degradation through the autophagy (autophagy) pathway. Additionally, PBA-1105 TFA enhances the autophagic flux of Ub-bound aggregates.

Apstatin TFA is a potent inhibitor of aminopeptidase P (APP), with Ki values of 2.6 µM for rat APP and 0.64 µM for human APP. This compound also exhibits cardioprotective properties.

DBCO-PEG6-amine (TFA) is a PROTAC linker classified within the PEG category, suitable for synthesizing PROTAC molecules. This compound is utilized as a click chemistry reagent and includes a DBCO group, enabling it to participate in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules.

Thalidomide-4-NH-PEG1-COOH TFA is a conjugate of an E3 ligase ligand and linker, composed of Thalidomide and NH-PEG3-NH-Boc. It serves as a Cereblon? ligand, facilitating the recruitment of CRBN? protein. This compound is a crucial intermediate in the synthesis of PROTAC molecules designed based on CRBN.

Glutathione arsenoxide (GSAO) TFA is a potential anticancer agent and tumor metabolism inhibitor. It specifically targets the adenine nucleotide translocase (ANT) on the mitochondrial inner membrane. This compound induces cell proliferation arrest and cell death. Additionally, Glutathione arsenoxide TFA can be utilized to identify cell surface proteins, including protein disulfide isomerase.

Gly-7-MAD-MDCPT (Compound 4b) TFA is an anticancer agent. This Camptothecin compound exhibits cytotoxicity against various cancer cell lines, with an IC50 range of 10-1000 nM.

(R,S,S)-VH032-Me-N-Boc-7-aminoheptanoic acid TFA is a conjugate that consists of an E3 ubiquitin ligase ligand and a linker. This compound is useful for synthesizing dTAGV-1 hydrochloride.

Protease-Activated Receptor-1 (PAR-1) Agonist TFA is a selective peptide that acts as an agonist for the proteinase-activated receptor-1 (PAR-1). Corresponding to the tethered ligand of PAR-1, this compound mimics the actions of thrombin through the PAR-1 receptor[1][2].

Angiotensin I/II (1-6) TFA is a chemical compound comprising amino acids 1-6, derived from the Angiotensin I/II peptide. This peptide is formed by the cleavage of angiotensinogen by renin, with Angiotensin I subsequently hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA), an 11-amino acid peptide, specifically binds to the Na+/K+-ATPase beta-subunit (ATP1B1), primarily interacting with its C-terminus, and enhances the transdermal delivery of various macromolecules[1].

Guanylin (human) TFA is a 15-amino acid peptide that serves as an endogenous activator of intestinal guanylate cyclase. This compound is primarily located in the gastrointestinal tract, where it regulates electrolyte and water transport in the intestinal and renal epithelia through a mechanism dependent on cyclic GMP. [1][2]

Lactoferricin B (4-14), bovine (TFA), is a peptide derived from residues 4-14 of bovine lactoferrin, exhibiting broad-spectrum antimicrobial activity against various microorganisms[1].

Arg-Gly-Asp-Cys TFA serves as the binding motif through which fibronectin interacts with cell adhesion molecules. This compound has the ability to hinder platelet aggregation and fibrinogen binding.

Tyrosylleucine (Tyr-Leu, YL) TFA is a dipeptide compound with potent antidepressant-like activity and demonstrates effective modulation of depressive symptoms when administered orally.